Excipient Selection for Oral Solid Dosage Forms

Why Excipient Selection Is Critical to Tablet and Capsule Development

Excipients in oral solid dosage forms serve multiple concurrent functions — and many individual excipients serve more than one simultaneously. A filler also provides compressibility. A disintegrant may also improve wettability. A binder used in wet granulation contributes to tablet hardness in ways that interact non-linearly with compression force. This functional interdependency means that excipient selection cannot be approached as a list of independent one-at-a-time decisions: the performance of the final formulation emerges from the interactions among all components, and the design of a formulation with predictable, reproducible quality requires a systematic framework that treats excipient type, grade, concentration, and ratio as interacting variables from the outset. Modern excipient selection frameworks draw on the ICH Q8(R2) quality by design (QbD) philosophy, in which the formulation design space — the combination of ingredient levels that delivers acceptable product quality — is characterised experimentally using design of experiments (DoE) rather than one-variable-at-a-time optimisation.

The regulatory dimension of excipient selection is equally important. Every excipient used in a pharmaceutical product intended for human use must be safe for the intended route of administration at the proposed concentration, and its use must be supported by either a compendial monograph (USP/NF, BP, or Ph. Eur.) or documented safety data. The FDA Inactive Ingredient Database (IID) is the primary reference for confirming that a given excipient has been previously approved for oral use and identifying the precedented concentration range — a critical input for CMC justification in NDA and ANDA submissions. Excipients used at concentrations above the IID precedent for the intended route require additional toxicological justification, adding regulatory complexity and timeline risk to the development programme.

Fillers and Diluents: Building the Compressible Tablet Matrix

Fillers — also called diluents — are the highest-concentration excipients in most tablet formulations, typically constituting 20–80% of total tablet mass. Their primary role is to provide sufficient bulk to make a tablet of processable size and weight when the API dose is low relative to the minimum tablet mass that can be reproducibly manufactured on a given tablet press. Beyond this bulking function, the choice of filler has profound consequences for the compaction and flow behaviour of the formulation: the dominant compaction mechanism of the filler — plastic deformation, brittle fracture, or a combination of both — determines the compaction pressure required to achieve target tablet hardness, the sensitivity of the formulation to over-lubrication, and the compatibility with direct compression versus granulation-based manufacturing routes.

Microcrystalline cellulose (MCC) is the single most widely used excipient in solid dosage formulation, valued for its exceptional compressibility through plastic deformation, its good intrinsic flow (particularly in coarser grades such as Avicel PH-102 and PH-200), its chemical inertness towards most APIs, and its established regulatory acceptance globally. MCC is the backbone filler for direct compression processes and is equally effective in wet and dry granulation formulations. Lactose — particularly spray-dried lactose grades engineered for direct compression — is the principal alternative, offering good flow, near-neutral taste, and broad compatibility, but is contraindicated for APIs containing primary or secondary amine groups due to Maillard condensation. Mannitol is preferred for chewable tablets and orally disintegrating formulations due to its pleasant, slightly sweet taste and cooling mouthfeel, and is also the standard bulking agent for lyophilised injectables as described in our pharmaceutical lyophilization guide. Dicalcium phosphate (anhydrous or dihydrate) provides excellent compressibility and is commonly used for high-dose API formulations where a non-cellulosic, calcium-containing filler is acceptable.

Co-Processed Excipients for Direct Compression

Co-processed excipients — manufactured by combining two or more excipients through a physical process such as co-spray drying, co-crystallisation, or fluid-bed agglomeration — have become standard tools for direct compression formulation development over the past two decades. Products such as MicroceLac 100 (MCC + lactose), StarLac (lactose + maize starch), and Cellactose 80 (cellulose + lactose) provide compressibility, flow, and disintegration properties superior to simple physical mixtures of their components, because the co-processing generates intimate particle-level integration that cannot be replicated by blending. For APIs that do not compress well at the concentrations required for their target tablet strength, co-processed excipients are often the enabling technology that makes direct compression feasible and eliminates the need for granulation.

Binders: Achieving Tablet Cohesion Through Granulation or Dry Compaction

Binders are excipients that promote adhesion between particles, either by forming a viscous solution that bridges particle contacts during wet granulation or by acting as solid-state bonding agents during dry compaction. The choice of binder — and the method of binder addition — is one of the most formulation-specific decisions in tablet development because binder performance depends heavily on the API's surface chemistry, the API loading, the granulation solvent system, and the drying conditions used downstream. A binder that produces ideal granule properties in one formulation may produce over-granulation, content non-uniformity, or dissolution failure in another with a different API or API concentration, making binder selection a candidate for systematic DoE-based optimisation rather than default substitution from previous formulations.

Polyvinylpyrrolidone (PVP, povidone) is the most widely used binder in pharmaceutical wet granulation, valued for its excellent solubility in both aqueous and organic solvents, its capacity to bind a wide range of API types, and its broad regulatory precedent across global markets. PVP grades K-25 and K-30 are the most commonly used in granulation, with K-30 typically providing slightly more cohesive granules at equivalent concentration. Hydroxypropyl methylcellulose (HPMC, hypromellose) and hydroxypropyl cellulose (HPC) are cellulose ether alternatives used where the slower granule dissolution kinetics of cellulosic binders are acceptable or beneficial for modified-release formulations — HPMC is also a primary matrix-forming polymer in hydrophilic matrix modified-release tablet systems. For dry granulation (roller compaction) processes, MCC itself serves as both filler and binder, with its plastic deformation properties generating sufficient interparticle bonding under the compaction pressure of the roller compactor to produce compactable ribbons.

Disintegrants: Enabling Rapid Drug Release After Tablet Ingestion

Disintegrants are excipients that facilitate the physical breakup of a compressed tablet into smaller fragments — and ideally into primary particles — after contact with gastrointestinal fluids, thereby exposing the maximum drug surface area for dissolution in the shortest possible time. For immediate-release formulations, rapid disintegration is a prerequisite for achieving the target dissolution profile specified in the pharmacopoeial monograph or product specification; inadequate disintegration is one of the most common root causes of dissolution failure and in vivo bioavailability problems identified during development and post-approval stability studies. The three superdisintegrants — croscarmellose sodium (CCS), sodium starch glycolate (SSG), and crospovidone (PVPP) — dominate modern immediate-release tablet formulation because they swell or absorb water at rates orders of magnitude faster than conventional disintegrants such as starch or microcrystalline cellulose used at the same concentration.

A pharmaceutical rotary tablet press at the compression station — the mechanical tolerances, punch geometry, and die fill depth are all directly influenced by the flow and compaction properties of the excipient blend, making excipient selection inseparable from process design.

Superdisintegrant Mechanisms and Selection

The three principal superdisintegrants differ in their primary mechanism of tablet disruption. Croscarmellose sodium (CCS, e.g., Ac-Di-Sol) swells extensively in both the transverse and longitudinal directions upon water absorption, generating internal expansion forces that fracture the tablet matrix. SSG (sodium starch glycolate, e.g., Explotab, Primojel) is a cross-linked starch derivative that absorbs water rapidly and swells to 300–600% of its original volume, producing rapid tablet disintegration at concentrations of 2–4% w/w. Crospovidone (PVPP, e.g., Kollidon CL) is a highly cross-linked insoluble PVP that disintegrates primarily through wicking and capillary action rather than swelling — making it particularly suitable for formulations where swelling-induced disintegration forces would cause fragmentation of a delicate modified-release coating layer. The USP Excipients monographs for each superdisintegrant specify identity and purity requirements that must be met by the manufacturer's certificate of analysis before release for pharmaceutical use.

Lubricants and Glidants: Flow and Compaction Process Enablers

Lubricants and glidants address the physical process challenges of powder handling and tablet compression: lubricants reduce the friction between the powder mass and the die wall during compression and ejection, preventing die wear and tablet sticking, while glidants reduce interparticle friction within the powder bulk to improve flowability and ensure consistent die fill from the feed hopper. Although these two excipient classes serve related functions, they operate by different physical mechanisms and are selected and optimised separately. Lubricant over-mixing — the single most common formulation manufacturing error — is discussed in the FAQ section below.

Magnesium stearate (MgSt) is used in the overwhelming majority of tablet formulations globally, at concentrations typically between 0.25% and 1.0% w/w, because of its outstanding lubricating efficiency at low concentrations and its very low cost. Its hydrophobic character — which causes the well-documented dissolution-retarding effect at higher concentrations or extended blending times — is managed through careful control of blending time and by choosing grades with defined specific surface areas (finer grades coat particle surfaces more effectively and therefore at lower concentrations). Where MgSt's hydrophobic character cannot be tolerated — for example, in rapidly dissolving immediate-release formulations or in formulations with APIs that are sensitive to alkaline microenvironments (MgSt is slightly alkaline and can catalyse certain degradation reactions) — sodium stearyl fumarate (Pruv) is the preferred alternative. Pruv is markedly less hydrophobic than MgSt, less sensitive to over-blending, and does not raise microenvironmental pH, making it the lubricant of choice for moisture-sensitive and pH-sensitive APIs. Colloidal silicon dioxide (fumed silica, e.g., Aerosil 200) is the standard glidant, used at 0.1–0.5% w/w to coat excipient and API particle surfaces, reducing van der Waals and electrostatic interparticle attractive forces that impair powder flow in hoppers and on press feeders.

Excipient-API Compatibility: Identifying and Avoiding Destructive Interactions

Excipient-API compatibility testing is a mandatory preformulation activity that precedes formulation design in all well-run pharmaceutical development programmes. Its purpose is to identify chemical or physical interactions between the API and candidate excipients that would cause potency loss, formation of toxic degradants, physical instability, or manufacturing problems — and to do so early enough in development to influence excipient selection before pilot-scale batches have been manufactured and before development timelines have been committed. The standard methodology involves preparing binary mixtures of the API with each candidate excipient at defined ratios and storing them under accelerated and stressed conditions, then analysing for changes in API assay, impurity profile, physical form, and appearance using HPLC, DSC, TGA, XRPD, and visual inspection.

The most clinically and regulatory consequential excipient-API incompatibilities encountered in solid dosage formulation include: Maillard condensation between reducing sugar fillers (lactose, glucose-based spray-dried lactose, sucrose) and APIs bearing primary or secondary amine groups — a reaction that is particularly problematic for amine-containing APIs at elevated temperature and humidity and generates coloured condensation products detectable as related substances by HPLC; peroxide-mediated oxidation of susceptible APIs (those containing thioether, secondary amine, or vinyl groups) catalysed by trace hydrogen peroxide impurities present in polyethylene glycols, polysorbates, and certain cellulose ether grades used as coating polymers or binders; and salt form conversion driven by excipients whose microenvironmental pH in the solid state is incompatible with the pKa of the API salt — a phenomenon particularly relevant for weakly basic or weakly acidic APIs formulated as sodium or hydrochloride salts, where a shift in microenvironmental pH above or below the API's pKa can drive conversion to the free form with consequent changes in solubility and dissolution rate. The ICH Quality Guidelines — particularly ICH Q1A(R2) on stability testing and ICH Q6A on specifications for new drug substances and drug products — provide the regulatory framework within which compatibility study results are interpreted and documented for submission.

Powder blend uniformity sampling across blend positions is a critical quality control step that directly reflects the quality of excipient selection and blending process design — non-uniform blends frequently trace back to poor excipient flow properties, inappropriate particle size ratios between API and filler, or inadequate glidant selection.

Manufacturing Process Considerations in Excipient Selection

Excipient selection and manufacturing process selection are inseparable decisions in tablet development: the choice of process — direct compression, wet granulation, dry granulation (roller compaction), or hot-melt extrusion — fundamentally constrains which excipients are suitable, and conversely, the physical properties of the API often dictate which process is feasible, which in turn governs excipient requirements. Formulation teams engaged with a specialist pharmaceutical solid dosage product development service should establish the process selection as one of the first formulation decisions, ideally informed by API physical property characterisation data — specifically particle size, bulk density, compressibility (Carr index), flowability (angle of repose, Hausner ratio), hygroscopicity, and intrinsic solubility — collected during preformulation.

Direct compression (DC) is the simplest and most cost-efficient process, avoiding the wet or dry granulation unit operations entirely, but requires that the powder blend as a whole — API plus all excipients — flows and compacts adequately. DC is feasible when the API loading is low (typically below 30–40% for most APIs without exceptional flow or compaction properties) and when DC-specific excipients (co-processed MCC grades, spray-dried lactose, co-processed systems) can compensate for the API's inherent processing limitations. Wet granulation — in which the powder blend is processed with a granulation liquid (typically aqueous or hydroalcoholic PVP or HPMC solution) and then dried and milled before compression — is used when the API or the required API loading precludes DC, when content uniformity cannot be achieved with direct compression of micronised API, or when the target dissolution profile requires the specific granule structure that wet granulation produces. For companies assessing the regulatory and cost implications of scale-up manufacturing without owning their own facility, the choice between DC and wet granulation has direct implications for the CDMO capabilities required and the technology transfer scope — topics covered in our guide on manufacturing without a factory.

The tablet coating step — applied after compression — introduces a further set of excipient decisions around polymer type, plasticiser, pigment, and coating process parameters. The tablet coating technology guide covers these considerations in detail. For enteric coatings and modified-release film coatings, the interaction between the coating polymer and the tablet core excipients (particularly at the coating-core interface) is an important stability consideration that must be addressed in accelerated stability studies. Moisture migration from an aqueous-applied coating into a hygroscopic tablet core is a well-documented mechanism by which coating processes introduce stability risks — and the risk is directly linked to the hygroscopicity of the core excipients, particularly the filler and binder selected in the primary formulation.